Evidence map›Paper›PMID 28073004›Full record

ArticleCancer cell2017

Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.

Veronica Veschi, Zhihui Liu, Ty C Voss, Laurent Ozbun, Berkley Gryder, Chunhua Yan, Ying Hu, Anqi Ma, Jian Jin, Sharlyn J Mazur and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. SGSS05-NS3, a covalent SETD8 inhibitor that activates p53 pathway in neuroblastoma.Journal of experimental & clinical cancer research : CR · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. C1QMolecular cancer · 2025
    Article
  17. Article
  18. Loss of NAT10 Reduces the Translation ofJournal of the American Heart Association · 2024
    Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 3 countries.

Veronica VeschiCell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105, Bethesda, MD 20892, USA.
Zhihui LiuCell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105, Bethesda, MD 20892, USA.
Ty C VossHigh-Throughput Imaging Facility, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Laurent OzbunHigh-Throughput Imaging Facility, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Berkley GryderOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Chunhua YanCenter for Biomedical Informatics and Information Technology, Center for Cancer Research, National Cancer Institute, Rockville, MD 20850, USA.
Ying HuCenter for Biomedical Informatics and Information Technology, Center for Cancer Research, National Cancer Institute, Rockville, MD 20850, USA.
Anqi MaDepartment of Structural and Chemical Biology, Oncological Sciences, Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jian JinDepartment of Structural and Chemical Biology, Oncological Sciences, Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Sharlyn J MazurChemical Immunology Section, Laboratory of Cell Biology, National Cancer Institute, Bethesda, MD 20892, USA.
Norris LamCell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105, Bethesda, MD 20892, USA.
Barbara K SouzaCell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105, Bethesda, MD 20892, USA.
Giuseppe GianniniIstituto Pasteur-Fondazione Cenci Bolognetti, Department of Molecular Medicine, University La Sapienza, 00161 Rome, Italy.
Gordon L HagerLaboratory of Receptor Biology and Gene Expression, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA.
Cheryl H ArrowsmithStructural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada.
Javed KhanOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Ettore AppellaChemical Immunology Section, Laboratory of Cell Biology, National Cancer Institute, Bethesda, MD 20892, USA.
Carol J ThieleCell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, CRC, 1-3940, 10 Center Drive MSC-1105, Bethesda, MD 20892, USA. Electronic address: ct47a@nih.gov.
National Cancer Institute · USIcahn School of Medicine at Mount Sinai · USIstituto Pasteur · ITNational Institutes of Health · USUniversity of Toronto · CA

Funding

Regulation of Differentiation of Pediatric Embryonal Tumors- NeuroblastomaZIABC010788 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI THIELE, CAROL J · 2009 to 2025
$29.7M
Tumor Suppressor Protein, p53ZIABC005599 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APPELLA, ETTORE · 2009 to 2025
$8.1M
Targeting High-risk Neuroblastoma using high through put siRNA screeningZIABC010806 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$7.8M
Discovery of Selective Inhibitors for Histone MethyltransferasesR01GM122749 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JIN, JIAN · 2017 to 2020
$1.3M
Creating in vivo Chemical Probes for Lysine Methyltransferases G9a and GLPR01GM103893 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JIN, JIAN · 2013 to 2015
$1.1M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC010788NIGMS NIH HHS R01 GM103893NIGMS NIH HHS R01 GM122749Wellcome Trust
6 · The paper itself

Abstract

Given the paucity of druggable mutations in high-risk neuroblastoma (NB), we undertook chromatin-focused small interfering RNA and chemical screens to uncover epigenetic regulators critical for the differentiation block in high-risk NB. High-content Opera imaging identified 53 genes whose loss of expression led to a decrease in NB cell proliferation and 16 also induced differentiation. From these, the secondary chemical screen identified SETD8, the H4

Indexed as

Epigenesis, GeneticCell DifferentiationCell ProliferationHistone-Lysine N-MethyltransferaseHumansNeuroblastomaQuinazolinesRNA, Small InterferingTumor Suppressor Protein p536,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amineHistone-Lysine N-MethyltransferaseKMT5A protein, humanQuinazolinesRNA, Small InterferingTP53 protein, humanTumor Suppressor Protein p53differentiationepigeneticsneuroblastomap53SETD8siRNA screen

Identifiers

PMID28073004
PMCPMC5233415
OpenAlexW2571353014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.